Novartis: FDA, EMA Accept Filings for Ofatumumab in Relapsing Multiple Sclerosis

Date : 02/24/2020 @ 5:34PM
Source : Dow Jones News
Stock : Novartis AG (NVS)
Quote : 84.85  -0.77 (-0.90%) @ 1:00AM
After Hours
Last Trade
Last $ 85.44 ▲ 0.59 (0.70%)

Novartis: FDA, EMA Accept Filings for Ofatumumab in Relapsing Multiple Sclerosis

Novartis (NYSE:NVS)
Historical Stock Chart

2 Months : From Feb 2020 to Apr 2020

Click Here for more Novartis Charts.

By Colin Kellaher


Novartis AG on Monday said the U.S. Food and Drug Administration and the European Medicines Agency accepted the company's applications seeking approval for ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults.

The Swiss drug maker said ofatumumab, if approved, has the potential to become a first-choice treatment for a broad patient population and the first B-cell therapy that can be self-administered at home using an autoinjector pen.

Novartis said the applications are based on Phase III studies in which ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate.

Novartis said it expects U.S. regulatory approval for ofatumumab in June and approval in Europe by the second quarter of 2021.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 24, 2020 12:19 ET (17:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.